<DOC>
	<DOCNO>NCT00599027</DOCNO>
	<brief_summary>The primary objective study explore efficacy Nasonex ( mometasone furoate nasal spray ) comparison placebo improve quality life subject moderate severe persistent allergic rhinitis intermittent asthma . A secondary objective evaluate efficacy Nasonex relieve subject 's symptom allergic rhinitis asthma .</brief_summary>
	<brief_title>An Exploratory Study Nasonex Patients With Moderate Severe Persistent Allergic Rhinitis Intermittent Asthma</brief_title>
	<detailed_description>The primary objective explore efficacy mometasone furoate nasal spray ( MFNS ) comparison placebo improve quality life subject moderate severe persistent allergic rhinitis intermittent asthma measure Rhinasthma Questionnaire ( Global Summary Score ) . In addition , two secondary objective . The first secondary objective evaluate efficacy MFNS improving quality life subject moderate severe persistent allergic rhinitis intermittent asthma measure Rhinasthma Upper Airways Score , Rhinasthma Lower Airways Score , Rhinasthma Respiratory Allergy Impact Score . The second secondary objective evaluate efficacy MFNS relieve subject 's symptom allergic rhinitis asthma measure Total 5 Symptoms Score ( T5SS ) Global Symptom Score ( T5SS+asthma symptom ) use rescue medication demand .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<criteria>Outpatients ( ≥18 ≤ 75 year age ) either sex Willingness participate comply procedure sign write informed consent Moderate/severe persistent allergic rhinitis history intermittent asthma least 2 year actual asthma ( symptom last 4 week ) To qualify randomization visit daily average T5SS [ ( Morningtime T5SS + Eveningtime T5SS ) /2 ] ≥ 6 least 4 day 1 week runin period Positive ( weal diameter &gt; 3 mm ) skin prick test ( SPT ) and/or CAPRAST ( class II high ) perform 6 month prior start trial require least house dust mite 1 pollen allergen ( grass Parietaria , IgE level &gt; 3.5 U/mL ) All prior medication washout time observed Female volunteer childbearing potential agree use medically accept method contraception surgically sterilize prior screen , receive protocolspecified medication , 30 day stop medication Negative urine pregnancy test Free clinically relevant disease would interfere study evaluation Able adhere dose visit schedule , agree record symptom severity score use IMP rescue medication daily diary Female intend become pregnant study within 12 week study completion Nursing , intend nursing study within 12 month study completion Taking medication prohibit study comply requirement designate washout period prohibit medication Anatomical abnormality nose ( turbinate hypertrophy , septal deviation , polyp ) Acute chronic sinusitis currently treat antibiotic and/or topical oral decongestant Rhinitis medicamentosa Evidence persistent asthma , asthma daytime nighttime symptom control shortacting beta2adrenoceptor agonist Asthma require chronic use inhale systemic corticosteroid Upper respiratory tract sinus infection require antibiotic therapy least 14day washout period prior runin period , viral upper respiratory infection within 7 day prior screen Dependence nasal , oral ocular decongestant , nasal topical antihistamine , nasal steroid Undergoing progressive course immunotherapy ( hyposensitization ) . Subjects regular maintenance schedule prior screen visit eligible study inclusion ; however , subject could receive hyposensitization treatment within 24 hour prior study visit Diagnosed cancer within past 5 year ( except successfully treat basal squamous cell carcinoma ) Concomitant medical problem Had follow clinical condition : active quiescent tuberculosis infection respiratory tract , untreated fungal , bacterial , systemic viral infection ocular herpes simplex Smoked smoke within previous 6 month Member staff , affiliate , family member staff personnel directly involve study Previously randomize study Any clinically significant deviation normal physical examination medical history could interfere study evaluation affect subject safety In situation condition could interfere participation study Used drug device investigational protocol 30 day prior visit 1 Participating clinical study Allergic sensitivity study drug excipients Compromised ability provide inform consent History noncompliance medication treatment protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>